Reply to the letter by Chatterjee et al "bleeding, mortality, and antiplatelet therapy: Results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial"

Jeffery S. Berger, Deepak L. Bhatt

Research output: Contribution to journalLetterpeer-review

Original languageEnglish
Pages (from-to)e3
JournalAmerican Heart Journal
Volume163
Issue number1
DOIs
StatePublished - Jan 2012
Externally publishedYes

Cite this